The Latest Breaking News from RBC Capital

RBC Capital analyst Ashish Sabadra lowered the price target for Verisk Analytics, Inc. (NASDAQ:VRSK) to $210 from $227 while maintaining the Outperform rating on the shares. The analyst expects 2Q22 revenues modestly below consensus as the tailwinds from strong insurance premium growth, international travel, and a potential uptick in auto insurance are more than offset…

RBC Capital has decided to maintain its Underperform rating of Enerpac Tool Group (NYSE:EPAC) and lower its price target from $19.00 to $18.00. Shares of Enerpac Tool Group are trading down 0.86% over the last 24 hours, at $18.34 per share.

Analysts lauded CarMax Inc's (NYSE:KMX) Q1 beat while also pointing out the macro concerns. RBC Capital analyst Steven Shemesh maintained CarMax with an Outperform and raised the price target from $104 to $108 in a note titled, "F1Q'23 Follow-Up – Navigating Volatility Well." KMX's results were broadly in line with expectations, Shemesh noted.  He expected the inflationary…

RBC Capital analyst Brad Erickson dove in deep with SMB-focused advertising agencies for near-term spending feedback and the ever-evolving competitive landscape across different ad channels. 

Wedbush analyst Nick Setyan lowered the price target on Darden Restaurants Inc (NYSE:DRI) to $122 (3% upside) from $140 and kept a Neutral rating on the shares. The analyst noted that FY23 guidance is predicated on normalization in inflation trends in the second half and has lowered his FY23 EPS estimate to $7.60 from $8.41…

RBC Capital has decided to maintain its Outperform rating of Accenture (NYSE:ACN) and lower its price target from $435.00 to $357.00. Shares of Accenture are trading up 2.58% over the last 24 hours, at $293.21 per share. A move to $357.00 would account for a 21.75% increase from the current…

Upgrades

RBC Capital analyst Mike Dahl further reduces estimates and price targets for Homebuilders & Building Products companies as housing demand declines. The analyst expects further deterioration after the most recent jump in rates (+50 bps past 2 weeks and +270 bps YTD).

RBC Capital says Edgewise Therapeutics Inc's (NASDAQ:EWTX) interim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy (BMD) improve reward/risk into October functional readout at 15 mg, which can help further de-risk the asset into the phase 2 BMD and Duchenne muscular dystrophy (DMD) studies. The analysts believe stable patient NSAAs in October…

Upgrades

RBC Capital cut Verizon Communications Inc. (NYSE: VZ) price target from $57 to $54. Verizon shares fell 0.9% to $50.22 in pre-market trading.